Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability

 

 Permissions and Reprints

Abstract

The development and progression of the complications of chronic diabetes mellitus are attributed not only to increased blood glucose levels but also to glycemic variability. Therefore, a deeper understanding of the role of glycemic variability in the development of diabetic complications may provide more insight into targeted clinical treatment strategies in the future. Previously, the mechanisms implicated in glycemic variability-induced diabetic complications have been comprehensively discussed. However, endothelial dysfunction and platelet hyperactivation, which are two newly recognized critical pathogenic factors, have not been fully elucidated yet. In this review, we first evaluate the assessment of glycemic variability and then summarise the roles of endothelial dysfunction and platelet hyperactivation in glycemic variability-induced complications of diabetes, highlighting the molecular mechanisms involved and their interconnections.

Publication History

Received: 08 January 2022

Accepted after revision: 30 May 2022

Article published online:
14 July 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Tuomilehto J, Lindstrom J, Eriksson JG. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
  Google Scholar
• 2 Dal Canto E, Ceriello A, Rydén L. et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26: 25-32
  CrossrefPubMedGoogle Scholar
• 3 Zaccardi F, Pitocco D, Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009; 25: 199-207
  CrossrefPubMedGoogle Scholar
• 4 Muggeo M, Verlato G, Bonora E. et al. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia 1995; 38: 672-679
  CrossrefPubMedGoogle Scholar
• 5 Muggeo M, Verlato G, Bonora E. et al. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997; 96: 1750-1754
  CrossrefPubMedGoogle Scholar
• 6 Zhou JJ, Koska J, Bahn G. et al. Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial. Diab Vasc Dis Res 2019; 16: 178-185
  CrossrefPubMedGoogle Scholar
• 7 Nordwall M, Arnqvist HJ, Bojestig M. et al. Good glycemic control remains crucial in prevention of late diabetic complications-the Linkoeping Diabetes Complications Study. Pediatr Diabetes 2009; 10: 168-176
  CrossrefPubMedGoogle Scholar
• 8 Sakamoto M. Type 2 Diabetes and glycemic variability: various parameters in clinical practice. J Clin Med Res 2018; 10: 737-742
  CrossrefPubMedGoogle Scholar
• 9 Monnier L, Colette C, Boegner C. et al. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom?. Diabetes Metab 2007; 33: 247-252
  CrossrefPubMedGoogle Scholar
• 10 Lachin JM, Bebu I, Bergenstal RM. et al. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care 2017; 40: 777-783
  CrossrefPubMedGoogle Scholar
• 11 Zhou JJ, Schwenke DC, Bahn G. et al. Glycemic variation and cardiovascular risk in the Veterans Affairs Diabetes Trial. Diabetes Care 2018; 41: 2187-2194
  CrossrefPubMedGoogle Scholar
• 12 Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care 2013; 36: S272-S275
  PubMedGoogle Scholar
• 13 Picard F, Adjedj J, Varenne O. Diabetes mellitus, a prothrombotic disease. Ann Cardiol Angeiol 2017; 66: 385-392
  PubMedGoogle Scholar
• 14 Tylee TS, Trence DL. Glycemic variability: looking beyond the A1C. Diabetes. Spectrum 2012; 25: 149-153
  PubMedGoogle Scholar
• 15 Pandit K. Continuous glucose concentration monitoring. Indian J Endocrinol Metab 2012; 16: S263-S266
  CrossrefPubMedGoogle Scholar
• 16 Monnier L, Colette C. Glycemic variability: should we and can we prevent it?. Diabetes Care 2008; 31: S150-S154
  CrossrefPubMedGoogle Scholar
• 17 Stratton IM, Adler AI, Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
  Google Scholar
• 18 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881-885
  CrossrefPubMedGoogle Scholar
• 19 Cameron FJ, Donath SM, Baghurst PA. Measuring glycaemic variation. Curr Diabetes Rev 2010; 6: 17-26
  CrossrefPubMedGoogle Scholar
• 20 Service FJ, Molnar GD, Rosevear JW. et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19: 644-655
  CrossrefPubMedGoogle Scholar
• 21 Kohnert KD, Heinke P, Vogt L. et al. Utility of different glycemic control metrics for optimizing management of diabetes. World J Diabetes 2015; 6: 17-29
  CrossrefPubMedGoogle Scholar
• 22 Hill HR, Hindmarsh PC, Stevens RJ. et al. A method for assessing quality of control from glucose profiles. Diabet Med 2007; 24: 753-758
  CrossrefPubMedGoogle Scholar
• 23 Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Therap 2009; 11: S55-S67
  CrossrefPubMedGoogle Scholar
• 24 Shima K, Tanaka R, Morishita S. et al. Studies on the etiology of “brittle diabetes”. Relationship between diabetic instability and insulinogenic reserve. Diabetes 1977; 26: 717-725
  CrossrefPubMedGoogle Scholar
• 25 Guillermo EU, Boris PK. Glycemic variability: how to measure and its clinical implication for type 2 diabetes. Am J Med Sci 2018; 356: 518-527
  CrossrefPubMedGoogle Scholar
• 26 Bergenstal RM. Glycemic variability and diabetes complications: does it matter? simply put, there are better glycemic markers!. Diabetes Care 2015; 38: 1615-1621
  CrossrefPubMedGoogle Scholar
• 27 Muggeo M, Zoppini G, Bonora E. et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: The Verona Diabetes Study. Diabetes Care 2000; 23: 45-50
  CrossrefPubMedGoogle Scholar
• 28 Bragd J, Adamson U, Backlund LB. et al. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?. Diabetes Metab 2008; 34: 612-616
  CrossrefPubMedGoogle Scholar
• 29 Kovatchev BP, Cox DJ, Gonder-Frederick LA. et al. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998; 21: 1870-1875
  CrossrefPubMedGoogle Scholar
• 30 Kovatchev BP. Metrics for glycaemic control–from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol 2017; 13: 425-436
  CrossrefPubMedGoogle Scholar
• 31 Alemzadeh R, Loppnow C, Parton E. et al. Glucose sensor evaluation of glycemic instability in pediatric type 1 diabetes mellitus. Diabetes Technol Ther 2003; 5: 167-173
  CrossrefPubMedGoogle Scholar
• 32 Kovatchev BP, Otto E, Cox D. et al. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006; 29: 2433-2438
  CrossrefPubMedGoogle Scholar
• 33 Service FJ, Nelson RL. Characteristics of glycemic stability. Diabetes Care 1980; 3: 58-62
  CrossrefPubMedGoogle Scholar
• 34 Ryan EA, Shandro T, Green K. et al. Assessment of the severity of hypoglycemia and glycemic lambility in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004; 53: 955-962
  CrossrefPubMedGoogle Scholar
• 35 Nusca A, Pantano AL, Melfi R. et al. Glycemic variability assessed by continuous glucose monitoring and short-term outcome in diabetic patients undergoing percutaneous coronary intervention: an observational pilot study. J Diabetes Res 2015; 250201
  PubMedGoogle Scholar
• 36 Metzger M, Leibovitz G, Wainstein J. et al. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002; 25: 1185-1191
  CrossrefPubMedGoogle Scholar
• 37 Danne T, Nimri R, Battelino T. et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017; 40: 1631-1640
  CrossrefPubMedGoogle Scholar
• 38 Battelino T, Danne T, Bergenstal RM. et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593-1603
  CrossrefPubMedGoogle Scholar
• 39 Kilpatrick ES. Arguments for and against the role of glucose variability in the development of diabetes complications. J. Diabetes Sci Technol 2009; 3: 649-655
  CrossrefPubMedGoogle Scholar
• 40 Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010; 12: 288-298
  PubMedGoogle Scholar
• 41 Caprnda M, Mesarosova D, Ortega PF. et al. Glycemic variability and vascular complications in patients with type 2 diabetes mellitus. Folia Medica 2017; 59: 270-278
  CrossrefPubMedGoogle Scholar
• 42 Paneni F, Costantino S, Cosentino F. Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. Cardiovasc Diagn Ther 2014; 4: 324-332
  PubMedGoogle Scholar
• 43 Jung HS. Clinical implications of glucose variability: chronic complications of diabetes. Endorinol Metab 2015; 30: 167-174
  PubMedGoogle Scholar
• 44 Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab 2013; 15: 3-8
  CrossrefPubMedGoogle Scholar
• 45 Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77-82
  CrossrefPubMedGoogle Scholar
• 46 Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care 2013; 36: S272-S275
  CrossrefPubMedGoogle Scholar
• 47 Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010; 12: 288-298
  CrossrefPubMedGoogle Scholar
• 48 Cardoso CRL, Leite NC, Moram CBM. et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol 2018; 17: 33
  CrossrefPubMedGoogle Scholar
• 49 Lachin JM, Genuth S, Nathan DM. et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008; 57: 995-1001
  CrossrefPubMedGoogle Scholar
• 50 Smith-Palmer J, Brandle M, Trevisan R. et al. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract 2014; 105: 273-284
  CrossrefPubMedGoogle Scholar
• 51 DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983
  CrossrefPubMedGoogle Scholar
• 52 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376: 124-136
  CrossrefPubMedGoogle Scholar
• 53 Hsu CR, Chen TY, Sheu WHH. Glycemic variability and diabetes retinopathy: a missing link. J Diabetes Complicat 2015; 29: 302-306
  CrossrefPubMedGoogle Scholar
• 54 Schreur V, van Asten F, Ng H. et al. Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus. Acta Ophthalmol 2018; 96: 459-464
  CrossrefPubMedGoogle Scholar
• 55 Yang YF, Li TC, Li CI. et al. Visit-to-visit glucose variability predicts the development of end-stage renal disease in type 2 diabetes: 10-year follow-up of Taiwan diabetes study. Medicine 2015; 94: e1804
  CrossrefPubMedGoogle Scholar
• 56 Kwai NCG, Arnold R, Poynten AM. et al. Association between glycemic variability and peripheral nerve dysfunction in type 1 diabetes. Muscle Nerve 2016; 54: 967-969
  CrossrefPubMedGoogle Scholar
• 57 Nyiraty S, Pesei F, Orosz A. et al. Cardiovascular autonomic neuropathy and glucose variability in patients with Type 1 diabetes: is there an association?. Front Endocrinol 2018; 9: 174
  CrossrefPubMedGoogle Scholar
• 58 Matsutani D, Sakamoto M, Iuchi H. et al. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol 2018; 17: 36
  CrossrefPubMedGoogle Scholar
• 59 Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol 2019; 7: 221-230
  CrossrefPubMedGoogle Scholar
• 60 Yang CP, Li Cl, Lin WY. et al. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM. Neurology 2017; 88: 944-951
  CrossrefPubMedGoogle Scholar
• 61 Anand SS, Islam S, Rosengren A. et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29: 932-940
  CrossrefPubMedGoogle Scholar
• 62 Zhang X, Xu X, Jiao X. et al. The effects of glucose fluctuation on the severity of coronary artery disease in type 2 diabetes mellitus. J. Diabetes Res 2013; 2013: 576916
  CrossrefPubMedGoogle Scholar
• 63 Beliaeva N, Strongin L, Baranov E. The impact of glycemic variability on local contractility of the left ventricular in acute period of myocardial infarction. Cardiology 2013; 126: 93
  PubMedGoogle Scholar
• 64 Gerbaud E, Darier R, Montaudon M. et al. Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome. Diabetes Care 2019; 42: 674-681
  CrossrefPubMedGoogle Scholar
• 65 Takahashi H, Iwahashi N, Kirigaya J. et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol 2018; 17: 116
  CrossrefPubMedGoogle Scholar
• 66 Francesco M, Lorenzo C, Domenico C. Glycaemic control and vascular complications in diabetes mellitus type 2. Adv Exp Med Biol 2021; 1307: 129-152
  PubMedGoogle Scholar
• 67 Huang J, Zhang X, Li J. et al. Impact of glucose fluctuation on acute cerebral infarction in type 2 diabetes. Can J Neurol Sci 2014; 41: 486-492
  CrossrefPubMedGoogle Scholar
• 68 Wattankit K, Folsom AR, Selvin E. et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2005; 180: 389-397
  CrossrefPubMedGoogle Scholar
• 69 Yang CP, Lin CC, Li CL. et al. Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes. Cardiovasc Diabetol 2020; 19: 4
  CrossrefPubMedGoogle Scholar
• 70 Tabit CE, Chung WB, Hamburg NM. et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11: 61-74
  CrossrefPubMedGoogle Scholar
• 71 Carrizzo A, Lzzo C, Oliveti M. et al. The main determinants of diabetes mellitus vascular complications: endothelial dysfunction and platelet hyperaggregation. Int J Mol Sci 2018; 19: 2968
  CrossrefPubMedGoogle Scholar
• 72 Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes 2017; 9: 434-449
  CrossrefPubMedGoogle Scholar
• 73 Jung HS. Clinical implications of glucose variability: chronic complications of diabetes. Endocrinol Metab 2015; 30: 167-174
  CrossrefPubMedGoogle Scholar
• 74 Cerielo A, Taboga C, Tonutti L. et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002; 106: 1211-1218
  CrossrefPubMedGoogle Scholar
• 75 Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol 2019; 11: 45-63
  PubMedGoogle Scholar
• 76 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
  CrossrefPubMedGoogle Scholar
• 77 Monnier L, Mas E, Ginet C. et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687
  CrossrefPubMedGoogle Scholar
• 78 Wang J-S, Huang Y, Zhang S. et al. A protective role of paeoniflorin in fluctuant hyperglycemia induced vascular endothelial injuries through anti-oxidative and anti-inflammatory effects and reduction of PKCβ1. Oxid Med Cell Longev 2019; 5647219
  PubMedGoogle Scholar
• 79 Risso A, Mercuri F, Quagliaro L. et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001; 281: E924-E930
  CrossrefPubMedGoogle Scholar
• 80 Quagliaro L, Piconi L, Assaloni R. et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003; 52: 2795-2804
  CrossrefPubMedGoogle Scholar
• 81 Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006; 147: S193-S201
  CrossrefPubMedGoogle Scholar
• 82 Forte M, Conti V, Damato A. et al. Targeting nitric oxide with natural derived compounds as a therapeutic strategy in vascular diseases. Oxid Med Cell Longev 2016; 7364138
  PubMedGoogle Scholar
• 83 Tousoulis D, Kampoli AM, Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol 2011; 10: 19-32
  CrossrefPubMedGoogle Scholar
• 84 Puca AA, Carrizzo A, Ferrario A. et al. Endothelial nitric oxide synthase, vascular integrity and human exceptional longevity. Immun Ageing 2012; 9: 26
  CrossrefPubMedGoogle Scholar
• 85 Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Investig 1997; 100: 2153-2157
  CrossrefPubMedGoogle Scholar
• 86 Halim M, Halim A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes Metab Syndr 2019; 13: 1165-1172
  CrossrefPubMedGoogle Scholar
• 87 Otsuka A, Azuma K, Iesaki T. et al. Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia 2005; 48: 2667-2674
  CrossrefPubMedGoogle Scholar
• 88 Watada H, Azuma K, Kawamori R. Glucose fluctuation on the progression of diabetic macroangiopathy-new findings from monocyte adhesion to endothelial cells. Diabetes Res Clin Pract 2007; 77: S58-S61
  CrossrefPubMedGoogle Scholar
• 89 Mita T, Otsuka A, Azuma K. et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2008; 358: 679-685
  CrossrefPubMedGoogle Scholar
• 90 Piconi L, Quagliaro L, Da Ros R. et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004; 2: 1453-1459
  CrossrefPubMedGoogle Scholar
• 91 Quagliaro L, Piconi L, Assaloni R. et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005; 183: 259-267
  CrossrefPubMedGoogle Scholar
• 92 Liu T, Gong J, Chen Y. et al. Periodic vs constant high glucose in inducing pro-inflammatory cytokine expression in human coronary artery endothelial cells. Inflamm Res 2013; 62: 697-701
  CrossrefPubMedGoogle Scholar
• 93 Esposito K, Nappo F, Marfella R. et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072
  CrossrefPubMedGoogle Scholar
• 94 Shanmugam N, Reddy MA, Guha M. et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003; 52: 1256-1264
  CrossrefPubMedGoogle Scholar
• 95 Wu N, Shen HT, Liu HN. et al. Acute blood glucose fluctuation enhances rat aorta endothelial cell apoptosis, oxidative stress and pro-inflammatory cytokine expression in vivo. Cardiovasc Diabetol 2016; 15: 109
  CrossrefPubMedGoogle Scholar
• 96 Buch A, Kaur S, Nair R. et al. Platelet volume indices as predictive biomarkers for diabetic complications in type 2 diabetic patients. J Lab Physicians 2017; 9: 84-88
  Article in Thieme ConnectPubMedGoogle Scholar
• 97 Gaiz A, Mosawy S, Colson N. et al. Thrombotic and cardiovascular risks in type two diabetes; Role of platelet hyperactivity. Biomed Pharmacother 2017; 94: 679-686
  CrossrefPubMedGoogle Scholar
• 98 Rollini F, Franchi F, Muñiz-Lozano A. et al. Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl Res 2013; 6: 329-345
  CrossrefPubMedGoogle Scholar
• 99 Ang L, Palakodeti V, Khalid A. et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2009; 52: 1052-1059
  CrossrefPubMedGoogle Scholar
• 100 Kodiatte TA, Manikyam UK, Rao SB. et al. Mean platelet volume in Type 2 diabetes mellitus. J Lab Physicians 2012; 4: 5-9
  Article in Thieme ConnectPubMedGoogle Scholar
• 101 Walinjkar RS, Khadse S, Kumar S. et al. Platelet indices as a predictor of microvascular complications in type 2 diabetes. Indian J Endocrinol Metab 2019; 23: 206-210
  CrossrefPubMedGoogle Scholar
• 102 Davì G, Catalano I, Averna M. et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774
  CrossrefPubMedGoogle Scholar
• 103 Gresele P, Guglielmini G, De Angelis M. et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-1020
  PubMedGoogle Scholar
• 104 Davi G, Alessandrini P, Mezzetti A. et al. In vivo formation of 8-Iso-Prostaglandin F-2 alpha is increased in hypercholesterolemia. An aspirin-insensitive amplification mechanism of platelet activation. Thromb Res 1998; 91: S131
  PubMedGoogle Scholar
• 105 Basili S, Pacini G, Guagnano MT. et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2008; 48: 2531-2538
  CrossrefPubMedGoogle Scholar
• 106 Huang Y, Wang J-S, Yang L. et al. Paeoniflorin ameliorates glycemic variability-induced oxidative stress and platelet activation in HUVECs and DM rats. RSC Adv 2020; 10: 42605-42612
  CrossrefPubMedGoogle Scholar
• 107 Linden MD, Tran H, Woods R. et al. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012; 38: 200-212
  Article in Thieme ConnectPubMedGoogle Scholar
• 108 Tang WH, Stitham J, Gleim S. et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 2011; 121: 4462-4476
  CrossrefPubMedGoogle Scholar
• 109 Vinik AI, Erbas T, Park TS. et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485
  CrossrefPubMedGoogle Scholar
• 110 Tschoepe D. The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21: 152-160
  Article in Thieme ConnectPubMedGoogle Scholar
• 111 Assert R, Scherk G, Bumbure A. et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44: 188-195
  CrossrefPubMedGoogle Scholar
• 112 Millican SA, Schultz D, Bagga M. et al. Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Free Rad Res 1998; 28: 533-542
  CrossrefPubMedGoogle Scholar
• 113 Ferretti G, Rabini RA, Bacchetti T. et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87: 2180-2184
  CrossrefPubMedGoogle Scholar
• 114 Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 2007; 7: 223-227
  CrossrefPubMedGoogle Scholar
• 115 Kessler L, Wiesel ML, Attali P. et al. Von Willebrand factor in diabetic angiopathy. Diabetes Metab 1998; 24: 327-336
  PubMedGoogle Scholar
• 116 Gresele P, Guglielmini G, De Angelis M. et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-1020
  CrossrefPubMedGoogle Scholar
• 117 Patti G, Cavallari I, Andreotti F. et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 2019; 16: 113-130
  CrossrefPubMedGoogle Scholar
• 118 Nusca A, Tuccinardi D, Pieralice S. et al. Platelet effects of anti-diabetic therapies: new perspectives in the management of patients with diabetes and cardiovascular disease. Front Pharmacol 2021; 12: 670155
  CrossrefPubMedGoogle Scholar
• 119 King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999; 48: 643-648
  CrossrefPubMedGoogle Scholar
• 120 Lehert P, Bets D, Donker AJ. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169: 616-625
  CrossrefPubMedGoogle Scholar
• 121 Schaeffer G, Wascher TC, Kostner GM. et al. Alterations in platelet Ca²⁺signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia 1999; 42: 167-176
  CrossrefPubMedGoogle Scholar
• 122 Spinetti G, Kraenkel N, Emanueli C. et al. Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res 2008; 78: 265-273
  CrossrefPubMedGoogle Scholar
• 123 Frankel DS, Meigs JB, Massaro JM. et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: The framingham offspring study. J Vasc Surg 2009; 50: 235
  CrossrefPubMedGoogle Scholar
• 124 van Schie MC, de Maat MP, Isaacs A. et al. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117: 1393-1399
  CrossrefPubMedGoogle Scholar
• 125 Xiang Y, Cheng J, Wang D. et al. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015; 125: 3377-3387
  CrossrefPubMedGoogle Scholar
• 126 Etheresia P. Platelets as potent signaling entities in type 2 diabetes mellitus. Trends Endocrinol Metab 2019; 30: 532-545
  CrossrefPubMedGoogle Scholar
• 127 Quehenberger P, Bierhaus A, Fasching P. et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000; 49: 1561-1570
  CrossrefPubMedGoogle Scholar
• 128 Xu B, Chibber R, Ruggiero D. et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-1291
  CrossrefPubMedGoogle Scholar
• 129 Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438
  CrossrefPubMedGoogle Scholar
• 130 Hangaishi M, Taguchi J, Miyata T. et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem. Biophys Res Commun 1998; 248: 285-292
  CrossrefPubMedGoogle Scholar
• 131 Gawlowski T, Stratmann B, Ruetter R. et al. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009; 48: 475-481
  CrossrefPubMedGoogle Scholar
• 132 Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012; 119: 6136-6144
  CrossrefPubMedGoogle Scholar
• 133 Zhang X, Zhang J, Li J. et al. Relationship between 24h venous blood glucose variation and mortality among patients with acute respiratory failure. Sci Rep 2021; 11: 7747
  CrossrefPubMedGoogle Scholar